Skip Navigation

Cardiovascular Research 2004 63(1):161-167; doi:10.1016/j.cardiores.2004.03.008
© 2004 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Widder, J.
Right arrow Articles by Bauersachs, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Widder, J.
Right arrow Articles by Bauersachs, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2004, European Society of Cardiology

Vascular endothelial dysfunction and superoxide anion production in heart failure are p38 MAP kinase-dependent

Julian Widdera,1, Thomas Behrb,1, Daniela Fraccarolloa, Kai Hua, Paolo Galuppoa, Piet Tasc, Christiane E Angermannb, Georg Ertla and Johann Bauersachs*,a

aMedizinische Klinik, Julius-Maximilians-Universität, Würzburg, Germany
bMedizinische Poliklinik, Julius-Maximilians-Universität, Würzburg, Germany
cKlinik für Anästhesiologie, Julius-Maximilians-Universität, Würzburg, Germany

*Corresponding author. Medizinische Universitätsklinik, Josef-Schneider-Strasse 2, D-97080 Würzburg, Germany. Tel.: +49-931-2011; fax: +49-931-201-36302. Email address: bauersachs_j{at}medizin.uni-wuerzburg.de

Objective: The mitogen-activated protein (MAP) kinase system, especially the p38 MAP kinase, is activated in chronic heart failure (CHF). However, the role of vascular p38 MAP kinase in CHF has not been analyzed yet. Methods and results: In aortic rings from rats with CHF 10 weeks after myocardial infarction, acetylcholine-induced relaxation was attenuated (maximum relaxation, Rmax: 54±5%) compared to sham-operated animals (Rmax: 77±5%, p<0.01), while endothelium-independent relaxation elicited by sodium nitroprusside was not significantly changed. Aortic levels of phosphorylated p38 MAP kinase protein were significantly elevated in rats with CHF. In addition, phosphorylation of MAP kinase-activated protein kinase-2 (MAPKAPK-2), an index of p38 MAP kinase activity, was increased. Aortic superoxide anion generation was significantly enhanced in rats with CHF accompanied by elevation of the NAD(P)H oxidase subunit p47phox protein expression. Inhibition of p38 MAP kinase by treatment with the p38 MAP kinase inhibitor SB239063 (800 ppm in standard rat chow) reduced MAPKAPK-2 phosphorylation, preserved acetylcholine-induced relaxation (Rmax: 80±4%, p<0.01), and reduced vascular superoxide formation. SB239063 treatment did not affect blood pressure and left ventricular enddiastolic pressure. In aortic tissue from CHF animals treated with the angiotensin-converting enzyme (ACE) inhibitor trandolapril, p38 MAP kinase phosphorylation was significantly reduced. Conclusions: Vascular p38 MAP kinase is markedly activated in rats with CHF. Chronic p38 MAP kinase inhibition with SB239063 prevented endothelial vasomotor dysfunction through reduction of superoxide anion production.

KEYWORDS Endothelial function; MAP kinase; Myocardial infarction; Oxygen radicals; Rats

1 These authors contributed equally to this work.

Time for primary review 9 days


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
R. N. Willette, M. E. Eybye, A. R. Olzinski, D. J. Behm, N. Aiyar, K. Maniscalco, R. G. Bentley, R. W. Coatney, S. Zhao, T. D. Westfall, et al.
Differential Effects of p38 Mitogen-Activated Protein Kinase and Cyclooxygenase 2 Inhibitors in a Model of Cardiovascular Disease
J. Pharmacol. Exp. Ther., September 1, 2009; 330(3): 964 - 970.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
R. P. Weerackody, D. J. Welsh, R. M. Wadsworth, and A. J. Peacock
Inhibition of p38 MAPK reverses hypoxia-induced pulmonary artery endothelial dysfunction
Am J Physiol Heart Circ Physiol, May 1, 2009; 296(5): H1312 - H1320.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
R. Dworakowski, S. Walker, A. Momin, J. Desai, A. El-Gamel, O. Wendler, M. T. Kearney, and A. M. Shah
Reduced Nicotinamide Adenine Dinucleotide Phosphate Oxidase-Derived Superoxide and Vascular Endothelial Dysfunction in Human Heart Failure
J. Am. Coll. Cardiol., April 8, 2008; 51(14): 1349 - 1356.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
O. Tenhunen, Y. Soini, M. Ilves, J. Rysa, J. Tuukkanen, R. Serpi, H. Pennanen, H. Ruskoaho, and H. Leskinen
p38 Kinase rescues failing myocardium after myocardial infarction: evidence for angiogenic and anti-apoptotic mechanisms
FASEB J, September 1, 2006; 20(11): 1907 - 1909.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
C.-F. Lam and Z. S. Katusic
Genetic modification of vascular endothelial function as therapeutic strategy in heart failure
Am J Physiol Heart Circ Physiol, August 1, 2005; 289(2): H518 - H519.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.